Liquidia enters Treprostinil Injection collaboration with Sandoz, Mainbridge

Liquidia announced a collaboration with Sandoz and Mainbridge Health Partners to support the development of a new subcutaneous pump for infusion of Treprostinil Injection, a generic form of Remodulin, for which Liquidia has the exclusive rights to promote and commercialize with Sandoz. To enable the collaboration, Sandoz and Liquidia will enter into a joint agreement with Mainbridge. Mainbridge will perform all development, validation and testing activities required for the pump and related consumables. The parties anticipate submitting a 510(k) in 2023 for FDA clearance. Sandoz and Liquidia will split equally the development costs. In connection with the execution of the Pump Agreement, Liquidia and Sandoz also agreed to extend their promotion agreement for Treprostinil Injection by another five years until December 31, 2032.